Pharma

Pharma 4.0 Market is Booming and Expected to Reach $52.41 Billion by 2031 - Explained Details | Updated InsightAce Study

Retrieved on: 
Wednesday, December 13, 2023
Carnival Corporation & plc, Palo Alto Networks, ABB, COVID-19, 4.0, Automation, Digital, IBM Consulting, Digital transformation, Partnership, Digitalization, Growth, Knowledge, Pharma, Fine chemical

Pharma 4.0 technology also aims to improve decision-making skills and provide in-line, real-time control over business, quality, operations, and regulatory compliance.

Key Points: 
  • Pharma 4.0 technology also aims to improve decision-making skills and provide in-line, real-time control over business, quality, operations, and regulatory compliance.
  • The North American pharma 4.0 market is anticipated to register a major market share in terms of revenue.
  • The development of new technologies is expected to significantly enhance the expansion of the Industry 4.0 market in the region.
  • The introduction of game-changing technology is predicted to cause a surge in the region's Industry 4.0 market.

Pharma 4.0 Market is Booming and Expected to Reach $52.41 Billion by 2031 - Explained Details | Updated InsightAce Study

Retrieved on: 
Wednesday, December 13, 2023
Carnival Corporation & plc, Palo Alto Networks, ABB, COVID-19, 4.0, Automation, Digital, IBM Consulting, Digital transformation, Partnership, Digitalization, Growth, Knowledge, Pharma, Fine chemical

Pharma 4.0 technology also aims to improve decision-making skills and provide in-line, real-time control over business, quality, operations, and regulatory compliance.

Key Points: 
  • Pharma 4.0 technology also aims to improve decision-making skills and provide in-line, real-time control over business, quality, operations, and regulatory compliance.
  • The North American pharma 4.0 market is anticipated to register a major market share in terms of revenue.
  • The development of new technologies is expected to significantly enhance the expansion of the Industry 4.0 market in the region.
  • The introduction of game-changing technology is predicted to cause a surge in the region's Industry 4.0 market.

IntegriChain and Blue Fin Group Pharma Trade and Distribution Experts to Speak at Informa Trade & Channel Strategies

Retrieved on: 
Tuesday, December 5, 2023
Trade, Partner (business rank), Wholesaling, Informa, Pulse, System, Pharma, PBM

PHILADELPHIA, Dec. 5, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that pharmaceutical strategy expert Bill Roth , General Manager and Managing Partner, Blue Fin Group, an IntegriChain Company, will be the keynote speaker at Informa's Trade & Channel Strategies conference.

Key Points: 
  • PHILADELPHIA, Dec. 5, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that pharmaceutical strategy expert Bill Roth , General Manager and Managing Partner, Blue Fin Group, an IntegriChain Company, will be the keynote speaker at Informa's Trade & Channel Strategies conference.
  • In addition, distribution experts David Weiss , IntegriChain Vice President of Industry Solutions, and Jason Bogroff , Blue Fin Group Partner, will speak at the event.
  • IntegriChain is a sponsor of the conference, which runs December 11 through 13 in Philadelphia.
  • Details of the highlighted sessions are as follows.

NEW EXECUTIVE POSITION ADDS TO LEADERSHIP TEAM TO POSITION KYTHERA FOR GROWTH OPPORTUNITIES

Retrieved on: 
Tuesday, December 5, 2023
NIAID, Research, AstraZeneca, Data science, Bio-Rad Laboratories, Disease, CSO, Patient, Health, Growth, AI, Knowledge, Biology, Thought, Drug development, Fine chemical, Pharma, Genentech

FRANKLIN, Tenn., Dec. 5, 2023 /PRNewswire/ -- Kythera Labs, a leading healthcare technology and data analytics company, announces the appointment of Glynn Dennis, Jr., Ph.D., as its new Chief Science Officer (CSO). Glynn joins the Kythera Labs executive team and leads Life Science and Pharma initiatives, including research and product development. Glynn has served in numerous scientific, data, and AI leadership roles across the industry, including at NIAID, Genentech, Bio-Rad Laboratories, and AstraZeneca. 

Key Points: 
  • Glynn joins the Kythera Labs executive team and leads Life Science and Pharma initiatives, including research and product development.
  • Glynn has served in numerous scientific, data, and AI leadership roles across the industry, including at NIAID, Genentech, Bio-Rad Laboratories, and AstraZeneca.
  • Kythera Labs will benefit from his leadership, building value through AI, data science, and research within Life Sciences as we position ourselves to accelerate our market opportunities and growth."
  • It's a pivotal moment in the industry, and Kythera Labs is very well-positioned to seize it," said Glynn Dennis, Jr., Ph.D.

Global Bio-India 2023 attracts global interest for India's $300 billion biotech potential from companies, academia, and start-ups

Retrieved on: 
Monday, December 4, 2023
Ministry, Department of Biotechnology, University of Illinois Urbana-Champaign, FDI, D, Ministry of Science, Public, PMO, Ethics, Government, Primary energy, SME, Ecosystem, USD, Independent, Valorisation, University, Medical laboratory scientist, Growth, Employment, DBT, Lignin, Pandemic, Renewable energy, Pharmaceutical industry, Science, Biotechnology, Pension, Health care, Pharma

Global Bio-India 2023 would be the largest congregation of biotech startups.

Key Points: 
  • Global Bio-India 2023 would be the largest congregation of biotech startups.
  • The central theme of Global Bio-India 2023 is Biotech Innovation and Bio-manufacturing.
  • Global Bio-India 2023 is not just an event; it's an opportunity to shape the future of biotechnology on a global scale  ( Source ).
  • The participation of US biotech leaders in India underscores the strategic importance of the collaboration between two global biotechnology giants.

Bushu Pharma Recognized with Frost & Sullivan's 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing and Robust Supply Chain Solutions

Retrieved on: 
Thursday, November 30, 2023
JPY, Research, SAN, GMP, Good manufacturing practice, CDMO, GTA, Frost, SCM, Temperature, Pharma, Fine chemical, Pharmaceutical industry

SAN ANTONIO, Nov. 30, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the contract development and manufacturing organization industry and, based on its findings, recognizes Bushu Pharma with the 2023 Japan Customer Value Leadership Award. Bushu Pharma is a market-leading contract manufacturing organization specializing in end-to-end pharmaceutical development, manufacturing, and supply chain management (SCM) solutions.

Key Points: 
  • Bushu Pharma produces high-quality pharmaceutical and medical devices with sophisticated quality control and supply chain management support that prioritizes customer value.
  • SAN ANTONIO, Nov. 30, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the contract development and manufacturing organization industry and, based on its findings, recognizes Bushu Pharma with the 2023 Japan Customer Value Leadership Award.
  • Bushu Pharma is a market-leading contract manufacturing organization specializing in end-to-end pharmaceutical development, manufacturing, and supply chain management (SCM) solutions.
  • Bushu Pharma sets itself apart by delivering world-class manufacturing expertise to worldwide drug innovators, meeting current stringent Good Manufacturing Practice (GMP) standards on a clinical and commercial scale.

Bushu Pharma Recognized with Frost & Sullivan's 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing and Robust Supply Chain Solutions

Retrieved on: 
Thursday, November 30, 2023
JPY, Research, SAN, GMP, Good manufacturing practice, CDMO, GTA, Frost, SCM, Temperature, Pharma, Fine chemical, Pharmaceutical industry

SAN ANTONIO, Nov. 30, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the contract development and manufacturing organization industry and, based on its findings, recognizes Bushu Pharma with the 2023 Japan Customer Value Leadership Award. Bushu Pharma is a market-leading contract manufacturing organization specializing in end-to-end pharmaceutical development, manufacturing, and supply chain management (SCM) solutions.

Key Points: 
  • Bushu Pharma produces high-quality pharmaceutical and medical devices with sophisticated quality control and supply chain management support that prioritizes customer value.
  • SAN ANTONIO, Nov. 30, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the contract development and manufacturing organization industry and, based on its findings, recognizes Bushu Pharma with the 2023 Japan Customer Value Leadership Award.
  • Bushu Pharma is a market-leading contract manufacturing organization specializing in end-to-end pharmaceutical development, manufacturing, and supply chain management (SCM) solutions.
  • Bushu Pharma sets itself apart by delivering world-class manufacturing expertise to worldwide drug innovators, meeting current stringent Good Manufacturing Practice (GMP) standards on a clinical and commercial scale.

Service Insight Unveils Revolutionary AIoT Solution for Biotech, Pharma, and Clinical Diagnostic Laboratories

Retrieved on: 
Wednesday, November 29, 2023
Cloud, Safety, Molecule, Internet of things, Organization, Artificial intelligence, Laboratory, Service, Drug discovery, Insight, Artificial intelligence of things, Ortho Clinical Diagnostics, Quality control, AI, Hospital, Retail, Pharmaceutical industry, Medical imaging, Diagnosis, Biotechnology, Pharma

Service Insight Unveils Revolutionary AIoT Solution for Biotech, Pharma, and Clinical Diagnostic Laboratories

Key Points: 
  • Service Insight Unveils Revolutionary AIoT Solution for Biotech, Pharma, and Clinical Diagnostic Laboratories
    In a data-centric era, laboratories in biotech, pharmaceuticals, and diagnostics are increasingly adopting AI to gain a competitive edge and make data-driven decisions.
  • To bridge this gap, Service Insight introduces the Smart Lab solution, a pivotal capability designed to capture essential missing data for driving AI models that address scientific reproducibility.
  • Anthony Uzzo, CEO of Service Insight, shares his vision: "At Service Insight, our mission is to be a catalyst for digital transformation in how businesses manage their operations.
  • Elevating Clinical Diagnostics & Hospital Labs:
    Service Insight introduces AIoT solutions to enhance efficiency and traceability in Clinical Diagnostic and Hospital Labs.

3-Hour Virtual Seminar on Root Cause Analysis, Corrective and Preventive Actions (CAPA) and Effectiveness Checks: Solving Problems at the Core, Proactive Quality Management, Organizational Excellence

Retrieved on: 
Friday, November 24, 2023
Root cause analysis, Cosmetics, Quality, Organization, Consent decree, Corrective and preventive action, CAPA, Pareto analysis, Diagram, Knowledge, Animal Health, Risk management, Fishbone, Plasma, Blood, Pharma

DUBLIN, Nov. 24, 2023 /PRNewswire/ -- The "3-Hour Virtual Seminar on Root Cause Analysis, CAPA and Effectiveness Checks" webinar has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 24, 2023 /PRNewswire/ -- The "3-Hour Virtual Seminar on Root Cause Analysis, CAPA and Effectiveness Checks" webinar has been added to ResearchAndMarkets.com's offering.
  • This comprehensive course offers essential knowledge and practical skills in root cause analysis, corrective and preventive actions (CAPA), and conducting effectiveness checks.
  • Participants will learn systematic approaches to identify root causes, develop effective CAPA plans, and assess the success of implemented solutions.
  • Join our interactive training course to gain a deep understanding of root cause analysis methodologies, including the 5 Whys, Fishbone (Ishikawa) Diagram, and Pareto Analysis.

Contract Logistics Market Size to Grow USD 505.3 Billion by 2031 at a CAGR of 7.5% | Valuates Reports

Retrieved on: 
Friday, November 24, 2023
Rail transport, Internet of things, Competitive landscape, Growth, Mode, Element, USD, Marketing, Health, Agility, Leg, Pharma, Warehouse, Arms industry, Transport, Others

The global contract logistics market size was valued at USD 243.6 Billion in 2021 and is projected to reach USD 505.3 Billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031.

Key Points: 
  • The global contract logistics market size was valued at USD 243.6 Billion in 2021 and is projected to reach USD 505.3 Billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031.
  • Major Factors Driving the Growth of Contract Logistics Market:
    The growth of the contract logistics market is aided by variables such as the e-commerce sector's expansion, the rise in trade-related agreements, and the manufacturing sector's expansion.
  • The e-commerce business has benefited greatly from logistics, and as a result, the use of logistics services has grown significantly, propelling the expansion of the contract logistics market.
  • Additionally, contract logistics businesses' ongoing efforts to provide effective last-mile deliveries are another potential driver anticipated to support the growth of the contract logistics market in the near future.